Hermes Biosciences Raises Seed Funding to Make Extracellular Vesicles a Practical Tool for Precision Medicine

▤ Summary

Hermes Biosciences has raised a seed round to commercialize an automated system for isolating extracellular vesicles. The company plans to launch its first commercial instrument in 2026 for clinical researchers and other customers that need standardized workflows. The platform promises higher yield, higher purity, and a fully automated process that outperforms ultracentrifugation and other current methods. Investors in the round include Genoa Ventures, Paladin Capital Group, and Vertical Venture Partners.

$ Funding

▦ Linked Companies